Answers are grounded in this paper and cite their sources.
Lung cancer continues to be a significant global health challenge, characterized by high mortality rates and limited treatment options in its advanced stages. However, the advent of immunotherapy has begun to transform the therapeutic landscape, offering new hope for pa-tients. This paper aims to provide a detailed analysis of the current state and prospects of im-munotherapy in the management of lung cancer. Specifically, it will offer a comprehensive his-torically review of recent clinical trials, emerging immunotherapeutic agents, predictive bi-omarkers, and novel targets for non-small cell lung cancer from the development of immuno-therapy for metastatic lung cancer to advances in immunotherapy in the neoadjuvant and ad-juvant setttings. Moreover, the paper will explore the challenges and opportunities associated with immunotherapy, including resistance mechanisms and the potential of combination ther-apies. Through this analysis, the paper intends to underscore the revolutionary impact of im-munotherapy on lung cancer treatment, advocating for the advancement of more personalized and efficacious therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Rosas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: